



DT06 Rec'd PCT/PTO

30 JUL 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application : Michael Valentine Agrez et al.  
Application No. : 10/019,816  
Filed : March 27, 2002  
For : A METHOD OF MODULATING INTEGRIN MEDIATED,  
CELLULAR ACTIVITY AND AGENTS USEFUL FOR SAME  
Attorney's Docket : SW-046XX

Group Art Unit: Unassigned

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope  
addressed to: Commissioner for Patents, Washington, D.C. 20231 on

July 24, 2012

By: Holliday C. Heine  
Holliday C. Heine, Ph.D.  
Registration No. 34,346  
Attorney for Applicant(s)

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

It is desired to cite for the record in this application the enclosed references listed on the attached copy of PTO Form #1449. The paragraph(s) marked below are applicable to this Information Disclosure Statement.

[ ] (1) Pursuant to 37 C.F.R. § 1.97(b)(1) and (2), the attached Information Disclosure Statement is being filed within three months of the filing date of the above identified national application or within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 of the above identified application. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.

- 1 -

Filed: March 27, 2002

Group Art Unit: Assigned

- [X] (2) Pursuant to 37 C.F.R. § 1.97(b)(3), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action on the merits. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.
- [ ] (3) Pursuant to 37 C.F.R. § 1.97(b)(4), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.
- [ ] (4) Pursuant to 37 C.F.R. § 1.97(c), the attached Information Disclosure Statement is being filed before the mailing date of a final action or a notice of allowance and is accompanied by:
- [ ] a statement under 37 CFR § 1.97(e); or
- [ ] the fee set forth in § 1.17(p).

PETITION UNDER 37 CFR § 1.97(d)

- [ ] (5) Pursuant to 37 CFR § 1.97(d), applicant(s) hereby petitions the Commissioner to consider the attached Information Disclosure Statement which is being filed on or before payment of the issue fee. This petition is accompanied by a statement under 37 C.F.R. § 1.97(e) and the petition fee set forth in 37 C.F.R. § 1.17(p).

STATEMENT UNDER 37 C.F.R. § 1.97(e)(1)

- [ ] (6) The undersigned hereby states that each item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

STATEMENT UNDER 37 C.F.R. § 1.97(e)(2)

- [ ] (7) The undersigned hereby states that no item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the attached Information Disclosure Statement was known to any individual designated in 37 C.F.R. §

Application No. 10/019,816  
Filed: March 27, 2002  
Group Art Unit: Assigned

1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

The filing of this Information Disclosure Statement is not a representation by the undersigned as to personal knowledge of the contents of every word or phrase of the material enclosed or that reliance on other suitably trained professionals has not been made.

If a search report of a searching agency is enclosed identifying the nature of the relevance of each document, such a designation is deemed to satisfy 37 C.F.R. § 1.98(a)(3) even if in a foreign language because the codes are the same in all languages. However, applicant(s) does not necessarily adopt the position reflected by that report.

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 23-0804. Triplicate copies of this letter are enclosed.

Respectfully submitted,


MICHAEL VALENTINE AGREZ

By: Holliday C. Heine  
Holliday C. Heine, Ph.D.  
Registration No. 34,346  
Attorney for Applicant(s)

WEINGARTEN, SCHURGIN,  
GAGNEBIN & LEBOVICI LLP  
Ten Post Office Square  
Boston, Massachusetts 02109

Telephone: (617) 542-2290  
Telecopier: (617) 451-0313

HCH/ad  
Enclosure  
274667-1



RECEIVED

U.S. PATENT AND TRADEMARK OFFICE

Date: July 24, 2002

Page 1 of 4

TECH CENTER 1600 2900

TECH CENTER 1600 2900

RECEIVED

Form PTO-1449 (REV. 07/01)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. SW-046XX	APPLICATION NO. 10 019,816
		INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		APPLICANT: Michael Valentine Agrez	
				FILING DATE March 27, 2002	GROUP

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE*

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES      NO

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)**

	Agrez, M.V. et al., "Colorectal cancer and the integrin family of cell adhesion receptors: current status and future directions", European Journal of Cancer 30A, 2166-2170 (1994)
	Agrez, M.V. et al., "Multiplicity of fibronectin-binding $\alpha v$ integrin receptors in colorectal cancer", Br. J. Cancer 73, 887-892 (1996).
	Agrez, M.V., "Cell adhesion molecules and colon cancer", A.N.Z.J. Surgery 66, 789-796 (1996).
	Bookstein, R. et al., "p53 gene therapy <i>in vivo</i> for hepatocellular and liver metastatic colorectal cancer", Seminars Oncol. 23, 66-77 (1996).
	Boulton, T.G. et al., "ERKs: a family of protein-serine threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF", Cell 65, 663-675 (1991).
	Cone, R.J. et al., "Effects of beta subunit cytoplasmic domain deletions on the recruitment of the integrin alpha v beta 6 to focal contacts", Cell Adhes. Comm. 2, 101-113 (1994).
	Coppolino, M. et al., "Inducible interaction of integrin alpha 2 beta 1 with calreticulin. Dependence of the activation state of the integrin", J. Biol. Chem. 270, 23132-23138 (1995).
	Gamble, J.R. et al., "Regulation of <i>in vitro</i> capillary tube formation by anti-integrin antibodies", J. Cell Biol. 121, 931-943 (1993).
	Garrington, T.P. et al., "Organization and regulation of mitogen-activated protein kinase signaling pathways", Curr. Opin. Biol. 11, 211-218 (1999).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED

JULY 30 2002

Date: July 24, 2002

Page 2 of 4

TECH CENTER 1600-2900  
SEP 25 2002

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 07/01) PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO. SW-046XX	APPLICATION NO. 10 019,816
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				APPLICANT: Michael Valentine Agrez	
				FILING DATE March 27, 2002	GROUP

#### U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE*

#### FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES      NO

#### OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Giancotti, F.G. et al., "Integrin signalling", Science 285, 1028-1032 (1999).
Gorgiglia and Kapikian, J., Virol. 66, 4407-4412 (1992).
Grammer, T.C. et al., "Evidence for MEK-independent pathways regulating the prolonged activation of the ERK-MAP kinases", Oncogene 14, 1635-1642 (1997).
Guan, J.L. et al., "Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation", Nature 358, 690-692 (1992).
Hannigan, G.E. et al., "Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase", Nature 379, 91-96 (1996).
Hemler, M.E., "Integrin associated proteins", Curr. Opin. Biol. 10, 578-585 (1998).
Hergott, G.J. et al., "Inhibition of retinal pigment epithelial cell migration and proliferation with monoclonal antibodies against the beta 1 integrin subunit during wound healing in organ culture", Invest. Ophthalmol. Vis. Sci. 34, 2761-2768 (1993).
Horwitz, A. et al., "Interaction of plasma membrane fibronectin receptor with talin-a transmembrane linkage", Nature 320, 531-533 (1986).
Howe, A. et al., "Integrin signaling and cell growth control", Curr. Opin. Biol. 10, 220-231 (1998).
Knezevic, I. et al., "Direct binding of the platelet integrin alpha IIb beta 3 (Gplllia) to talin. Evidence that interaction is mediated through the cytoplasmic domains of both alpha IIb and beta 3", J. Biol. Chem. 271, 16416-16421 (1996).
Kornberg, L. et al., "Cell adhesion or integrin clustering increases phosphorylation of a focal adhesion-associated tyrosine kinase", J. Biol. Chem. 267, 23439-23442 (1992).

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant	



RECEIVED

OCT 6 4 2002

Date: July 24, 2002

Page 3 of 4

TECH CENTER 1600 2900

TECH CENTER 1600 2900

SEP 25 2002

RECEIVED

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(REV. 07/01) PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
SW-046XXAPPLICATION NO.  
10 019,816

## APPLICANT:

Michael Valentine Agrez

FILING DATE

March 27, 2002

GROUP

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE*

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Loftus, J.C. et al., "Integrin-mediated cell adhesion: the extracellular face", J. Biol. Chem. 269, 25235-25238 (1994).
Miranti, C.K. et al., "Protein Kinase C regulates integrin-induced activation of the extracellular regulated kinase pathway upstream of Shc", J. Biol. Chem. 274, 10571-10581 (1999).
Otey, C.A. et al., "An interaction between alpha-actinin and the beta 1 integrin subunit in vitro", J. Cell Biol. 111, 721-729 (1990).
Payne, D.M. et al., "Identification of the regulatory phosphorylation sites in pp42 mitogen-activated protein kinase (MAP kinase)", EMBOJ 10, 885-892 (1991).
Pfaff, M. et al., "Integrin beta cytoplasmic domains differentially bind to cytoskeletal proteins", J. Biol. Chem. 273, 6104-6109 (1998).
Reszka, A.A. et al., "Identification of amino acid sequences in the integrin beta 1 cytoplasmic domain implicated in cytoskeletal association", J. Cell Biol. 117, 1321-1330 (1992).
Rojiani, M.V. et al., "In vitro interaction of a polypeptide homologous to human Ro SS-A antigen (calreticulin) with a highly conserved amino acid sequence in the cytoplasmic domain of integrin alpha subunits", Biochemistry 30, 9859-9866 (1991).
Schaller, M.D. et al., "Focal adhesion kinase and paxillin bind to peptides mimicking beta integrin cytoplasmic domains", J. Cell Biol. 130, 1181-1187 (1995).
Sheppard, D. et al., "Complete amino acid sequence of a novel integrin beta subunit (beta 6) identified in epithelial cells using the polymerase chain reaction", J. Biol. Chem. 265, 11502-11507 (1990).

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant	



RECEIVED

2002  
JUL 3 2002

Date: July 24, 2002

Page 4 of 4

TECH CENTER 1600/2000  
SEP 25 2002

Form PTO-1449 (REV. 07/01)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. SW-046XX	APPLICATION NO. 10 019,816
		INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>	APPLICANT: Michael Valentine Agrez	
			FILING DATE March 27, 2002	GROUP

#### U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE*

#### FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES      NO

#### OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

	Varner, J.A. et al., "Integrin alpha 5 beta 3 expression negatively regulates cell growth: reversal by attachment to fibronectin", Mol. Biol. Cell 6, 725-740 (1995).
	Wang, A. et al., "Differential regulation of airway epithelial integrins by growth factors", Am. J. Respir. Cell & Mol. Biol. 15, 664-672 (1996).
	Wary, K.K. et al., "The adaptor protein Shc couples a class of integrins to the control of cell cycle progression", Cell 87, 733-743 (1996).

EXAMINER	DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.